<br />
Treatment Strategies - Congress Review<br />
Long-Term E cacy and Safety Outcomes of PNH and<br />
aHUS Patients Treated with Soliris®<br />
Hannah Corby<br />
Treatment Strategies<br />
Introduction<br />
Paraoxysmal nocturnal hemoglobinuria (PNH) is a very rare blood<br />
disorder in which chronic, uncontrolled activation of complement, a<br />
component of the normal immune system, results in hemolysis; the<br />
destruction of the patient's red blood cells. PNH has been identi ed as<br />
occurring more commonly in patients with disorders of the bone marrow,<br />
including aplastic anemia (AA) and myelodysplastic syndromes (MDS).1-3<br />
Soliris® (eculizumab), a terminal complement inhibitor, speci cally targets<br />
uncontrolled complement activation, and extensive clinical trials have<br />
indicated that Soliris® signi cantly reduces hemolysis, which leads to an<br />
improvement in symptoms and a reduction in major health problems<br />
which are as<a title="Treatment Strategies - Hematology Volume 3 Issue 1 Alexion Article page 1" href="http://viewer.zmags.com/publication/c965b46a?page=1"> Treatment Strategies - Congress Review Long</a>
<a title="Treatment Strategies - Hematology Volume 3 Issue 1 Alexion Article page 2" href="http://viewer.zmags.com/publication/c965b46a?page=2"> highly signi cant improvement in symptoms and qua</a>
<a title="Treatment Strategies - Hematology Volume 3 Issue 1 Alexion Article page 3" href="http://viewer.zmags.com/publication/c965b46a?page=3"> Treatment Strategies - Congress Review to the </a>
<a title="Treatment Strategies - Hematology Volume 3 Issue 1 Alexion Article page 4" href="http://viewer.zmags.com/publication/c965b46a?page=4"> References 1. Wang H, Chuhjo T, Yasue S, et al. C</a>